Mice underwent a left mini-thoracotomy through the third intercostal space under endotracheal general anesthesia (Isoflurane 1%). The thymus and pre-aortic fat were retracted to expose the proximal ascending aorta. A PLGA (Fisher Scientific) miniature film (1x1.5 mm) carrying 2μg leptin (mouse leptin, Sigma, L3772) was applied to the anterior surface of the ascending aorta (see intra-operative photo, Figure S3 ). Control mice underwent application of a PLGA film devoid of the protein. The film was secured in position by the adjacent peri-vascular tissue. The left thoracotomy wound was closed when lungs were fully inflated to prevent residual pneumothorax using interrupted 7-0 peri-costal Dexon (polyglycolic acid) stitches. Intercostal muscles were approximated with similar stiches, and the skin closed with interrupted 7-0 monofilament (Prolene) stitch. Mice were kept under surveillance for up to 60 days, during which body weight, blood pressure measurement and echocardiographic examination (see below) of the ascending aorta and heart were performed weekly or bi-weekly, including a final examination prior to euthanasia.
AngII infusion/ Local LepA application model:
All mice were similarly treated and prepared for surgery as in the leptin application model. Through an identical left mini thoracotomy with exposure of the ascending aorta 3 miniature PLGA films (1x1.5) carrying the total of 5μg LepA (superactive mouse leptin antagonist, a D23L/L39A/D40A/F41A mouse leptin mutant obtained from Protein Laboratories Rehovot, Ltd.) 1 were applied to the proximal ascending aorta, at the same location like leptin was applied in the leptin application model. Immediately after chest closure an osmotic minipump (Alzet, pump model 2004) containing AngII (human AngII, A9525 Sigma) was implanted in the interscapular subcutaneous space for AngII infusion of 1000ng/kg/min and mice were subsequently followed for 28 days. During that period body weight, SBP, and echo of cardiovascular parameters was assessed (see below).
Blood pressure measurements:
Systemic blood pressure (SBP) measurements were performed using the BP-2000 Series II Blood Pressure Analysis System (Visitech Systems). Measurements were taken at baseline prior to surgery, then weekly for one month, and bi-weekly during the second month (in the leptin application model). Mice were trained on the BP system three times prior to baseline measurements. Two measurements per mouse were taken at every round. Each BP assessment per mouse consisted of 40 total measurements, once a minute. The first 10 measurements were discarded. Outliers were also excluded using the Chauvenet's criterion.
Echocardiography:
Echocardiography of the ascending aorta and left ventricle were performed at baseline, weekly/bi weekly (leptin model) and before termination of the experiment, using the Vevo 2100 system (Visualsonics). In each mouse, long axis and short axis B-mode views and videos were generated. Peak systolic velocity (PSV) was measured using Doppler mode at the LV outlet (aortic valve level). Accompanying software was used to measure aortic diameter and PSV. LV wall width and fraction area change (FAC) were extracted from videos generated by Vevo 2100 using custom MATLAB software. Experimental groups were blinded to the imager and analysts.
Mice tissues' analysis:
Mice were sacrificed with overdose anesthetic. The chest was opened to allow exposure of the heart and ascending aorta, followed by immediate perfusion fixation of the vascular tissues. A 10% formalin solution was infused through a LV puncture, flushing the heart and proximal aorta. The vascular organs, including the heart and full length aorta, were collected and exposed to further 8 hour fixation in 10% formalin, before being mounted in paraffin blocks.
Tissue 5μm sections on glass slides were deparaffinized and subjected to H&E staining or antibody retrieval in citric acid buffer (pH 6). Sections were then blocked with 0. Sigma #HT25A-1KT kit was used for Elastic Van Gieson staining. Image J software was used for quantification; experimental groups were blinded to analysts.
Human tissue samples:
The use of human tissues was approved by the Institutional Review Board of Sheba Medical Center, Tel Hashomer, Israel, and tissues were collected with informed consent.
Clinicaltrials.org identifier NCT00449306.
Surgical samples of ascending aortic aneurysm were collected (n=11) from patients with a variety of background diseases, including hypertension (10), hypercholesterolemia (5), diabetes mellitus (2), Marfan's syndrome (4), bicuspid aortic valve (2), and ankylosing spondylitis (1) (table S1). Four patients were operated urgently for type A dissection.
Samples of human stenotic aortic valves (n=11) were collected from patients undergoing aortic valve replacement surgery. Normal aortic valves (n=3) were obtained from explanted hearts of patients undergoing heart transplantation.
Human tissues' analysis:
Paraffin-embedded human tissues were sectioned at 4 to 6μm and stained with H&E and modified Movat's pentachrome. Parallel sections were exposed to antibodies specific for 
In situ mRNA hybridization:
Leptin mRNA in situ hybridization (ISH) was performed as previously described. 2 Briefly, 5μm paraffin sections were digested with proteinase K, followed by overnight incubations with human leptin RNA sense and antisense probes that had been in vitro transcribed and labeled with digoxigenin (Roche). Signals were visualized by antidigoxigenin AP antibodies (Roche) and nitroblue tetrazolium (Dako).
qPCR:
Reactions were performed on cDNA using an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) and Universal PCR Master Mix (Applied Biosystems) according to the manufacturer (Applied Biosystems). TaqMan probes and primers for leptin (assay ID number: HS00174877) and LepR (assay ID number: HS00174497) were 'assay-on-demand' gene expression products (Applied Biosystems). Total RNA converted to cDNA from two normal human aortic valves were used to establish a baseline for each detected gene to which all stenotic aortic valves (AVSs) samples were compared to.
Normalization was performed using the endogenous control gene Abl1 with the fluorescent probe 5'-Fam-CTGGCCCAACGATGGCGA-BHQ-3'.
The primers to Abl1 gene used were:
The results presented are fold changes based on the differences of normalized Ct values compared to control samples, assuming optimal primer efficiency (2^ΔΔCt). Results were analyzed using SDS 2.3 (Applied Biosystems) and Excel (Microsoft Corp) software.
In vitro studies:
Valve interstitial cells (VICs), cell culture:
Human VICs (generously provided by Kristyn S Masters) were grown in MEMα + 15% FCS + 1.5% PSN + 1% Glutamine + 2.5 μg/mL Amphotericin B [Complete medium].
Cultures were split 1 to 3 every week to 10 days or after reaching >80% confluence, the earlier of them. The cells grow as long spindles, transforming into star-shaped cells, forming colonies. Thereby, 80% confluence is relative to colonies' dimension more than surface covered. Medium was changed after 5-7 days in culture.
Proliferation experiments:
Cells were seeded in Complete medium in 24W plates (15,000 to 20,000 cells/well) and grown for 3-5 days, when the medium was changed to 1.5% FCS containing media for 48h (starvation period). Proliferation assay was performed in quadruplicates in fresh confluence were exposed to 1, 2.5 and 10 nM Angiotensin II (Sigma-Aldrich, St. Louis, MO, USA) for 4 and 24 hours in the same serum-containing medium. At the end of the incubation cultures were washed twice with complete DPBS (Biological Ind.) and total RNA was extracted using EZ-RNA (Biological Ind.) and the obtained RNA was dissolved in DEPC-treated water (Biological Ind.).
Statistics:
Two-sided Mann Whitney test was used to assess differences between Control and Leptin treated animals, or AngII vs. AngII and LepA treated animals. To overcome baseline variability between physiological parameters of ApoE-/-animals, each echo-cardiograph measurement at the end of the experiment was compared to a baseline measurement prior to surgery. All data is shown as mean ± standard error, and typical number of samples was 10 for mouse sample, and 5 for in vitro samples, as detailed in the figure captions. Figure 1 D-F) . αSMA staining marking smooth muscle cells (G) and CD68 marking macrophages (H). Scale bar=200μm. A. An Intra-operative view showing the slow release PLGA film (yellow outline) placed adjacent to the ascending aorta. This strategy was used to apply the leptin slow release film, leptin antagonist, and control films as described in this study. B. Weight of mice after receiving local leptin or control film. There was no significant difference in the weight between groups. N=10-11. C. Systolic blood pressure of mice after receiving local leptin or control film. There was no significant difference in blood pressure between groups. N=10-11. D. Increase in aortic valve regurgitation peak velocity following local treatment with leptin or control film. All animals displayed some regurgitation jet. Mean baseline velocity was 1000mm/sec. E. Increase in aortic valve regurgitation velocity time integral (VTI). 1 out of 12 control animals displayed above baseline regurgitation, defined as VTI at least 10-fold greater than mean, 0 of 10 treated animals had regurgitation. Mean baseline velocity time integral was 2.8mm F. Change in LV stroke area. N=10-11. Mean baseline stroke area was 5. 
